BofA analyst Joshua Dennerlein lowered the firm’s price target on Alexandria Real Estate (ARE) to $50 from $57 and keeps a Neutral rating on the shares after the company hosted its investor day this week. Management now expects the overall life science market to take 4-5 years to reach equilibrium, versus prior forecasts of 2-3 years, and Alexandria reduced the high end of its FY26 guidance that was initially provided with Q3 earnings, the analyst noted.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARE:
- Alexandria Real Estate price target lowered to $48 from $52 at Cantor Fitzgerald
- Alexandria Real Estate price target lowered to $64 from $72 at Evercore ISI
- Alexandria Real Estate price target lowered to $60 from $67 at BMO Capital
- Alexandria Real Estate price target lowered to $67 from $73 at Baird
- Alexandria Real Estate price target lowered to $52 from $61 at Citi